ArticleOphthalmology and therapy2022
Antiseptics and the Ocular Surface: In Vitro Antimicrobial Activity and Effects on Conjunctival and Corneal Epithelial Cells of a New Liposomal Ocular Spray Containing Biosecur
Article in Ophthalmology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- In Vitro Characterization of Insulin-Loaded Soft Contact Lenses and Their Effect on Corneal Epithelial Cell Viability and Permeability.Pharmaceutics · 2026Article
- In Vitro Activity of a New Ophthalmic Spray Containing BiosecurVision (Basel, Switzerland) · 2025Article
- Efficacy and Safety of Keratosept Eye Drops in Patients with Punctate Keratitis: Clinical and Microbiological Evaluation on 50 Eyes.Microorganisms · 2024Article
- Anti-Staphylococcal Biofilm Effects of a Liposome-Based Formulation Containing Citrus Polyphenols.Antibiotics (Basel, Switzerland) · 2024Article
- Anti-staphylococcal activity of a polyphenol-rich citrus extract: synergy with β-lactams and low proficiency to induce resistance.Frontiers in microbiology · 2024Article
- Prophylaxis of Ocular Infection in the Setting of Intraocular Surgery: Implications for Clinical Practice and Risk Management.Ophthalmology and therapy · 2023Review
- Broad-Spectrum Antimicrobial Activity of Oftasecur and Visuprime Ophthalmic Solutions.Microorganisms · 2023Article
- In praise of povidone-iodine application in ophthalmology.Survey of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe study aimed to evaluate the in vitro antimicrobial activity of a new liposomal ocular spray containing the antiseptic Biosecur
methodsMinimal inhibitory concentrations (MIC) and minimal bactericidal concentrations (MBC) of Oftasecur against Candida albicans and Gram-positive and Gram-negative bacteria, including antibiotic-resistant strains, were determined. Human corneal and conjunctival epithelial cells in vitro were incubated for 10 and 30 min with Oftasecur or its components. The cytotoxicity was assessed through the release of cytoplasmic enzyme lactate dehydrogenase (LDH) into the medium; the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed to evaluate the cell viability.
resultsOftasecur was active at dilutions ranging from 1:2 to 1:16 and it displayed bactericidal and fungicidal effect against all assayed microorganisms. Most of the reduction of Staphylococcus epidermidis vitality (65%) occurred within the first minute of exposure. The cytotoxicity of Oftasecur was similar to its vehicle, and the cell viability was significantly reduced only by Oftasecur in its undiluted form. Conversely, Biosecur induced a significant cytotoxicity in all the experiments.
conclusionOftasecur showed a rapid and wide-spectrum antibacterial activity, with an optimal in vitro tolerability profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.